ITMCTR2000003282
Not yet recruiting
Phase 1
Evaluation of clinical efficacy and safety of herbs of rich-Iodine for Graves' Hyperthyroidism (the HIGHT trial) patients with oral ATDs intolerant
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine0 sitesTBD
ConditionsGraves' disease
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Graves' disease
- Sponsor
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis criteria (Guidelines for Clinical Diagnosis and Treatment of thyroid disease in 2007, CSE)
- •1\. Clinical manifestations of hyperthyroidism;
- •2\. The presence of diffuse goiter;
- •3\. The suppressed serum TSH and elevated thyroid hormones (FT4 and FT3\);
- •4\. The presence of exophthalmos;
- •5\. The presence of Pretibial myxedema(PM);
- •6\. The presence of TSH\-Receptor Antibodies (TRAb/TSAB).
- •TCM symptoms criteria (Chinese New Medicine Treatment of Diabetes Clinical Research Guiding Principle) yin deficiency with heat.
- •Inclusion criteria
- •1\. Adults over 18 years to under 70 years of age;
Exclusion Criteria
- •1\. Hyperthyroidism crisis;
- •2\. Symptomatic compression or large goiter;
- •3\. Subjects who allergy to the components in TCM and/or placebo;
- •4\. Those who have thiocarbamides\-associated major side effects including of severe hepatitis(elevation of AST or ALT more than double the normal upper limit), agranulocytosis (neutrophil count \< 500/mL), severe exfoliative dermatitis;
- •5\. Women who are pregnant or lactating, or preparing for pregnancy and lactating women;
- •6\. Subjects with a history of alcohol abuse, drug abuse, or mental diseases;
- •7\. Those who are in seriously unstable medical condition, such as cardiovascular disease, cerebrovascular disease, hepatobiliary disease, renal disease or problems in the urinary reproductive system, or neoplasms, or whose treatment with any medication potentially influencing thyroid function (IFN\-gama, amiodarone, lithium, corticosteroids, etc.);
- •8\. Subjects who have taken other clinical trial drugs within 3 months;
- •9\. Subjects who are thought to be inappropriate for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
A clinical study to evaluate the efficacy and safety of the Vamana karma followed with two Rasayanas Takradhara and Rasaoushadi in treatment of psoriasis.Health Condition 1: null- Psoriasis (Kitibha)CTRI/2016/02/006631Central council for Research in Ayurvedic sciences CCRAS110
Completed
Phase 3
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2013012612274N1Vice-Chancellor for Research, Shahid Beheshti University of Medical Sciences100
Completed
Phase 3
Evaluation of the Clinical Safety and Efficacy of Suprimun in Renal Transplant RecipientsComparative Interventional Treatment for reduceing the renal transplant rejection.kidney transplant rejectionIRCT2014072118548N1Research Deputy of Kermanshah University Of Medical Sciences60
Active, not recruiting
Phase 4
Safety and effectiveness clinical evaluation of the range of injectable hyaluronic acid medical devices in facial aesthetic treatmentModerate to severe peri-oral lines, moderate to severe nasolabial folds, moderate to severe cheeks/cheekbones volume deficit, chin recursionSkin and Connective Tissue DiseasesISRCTN49836437Kylane Laboratoires SA68
Active, not recruiting
Phase 1
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.HypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-004891-16-LVInstitut de Recherches Internationales Servier968